T he goals of a general anesthetic are to achieve hypnosis, amnesia, analgesia, control of autonomic responses, and muscle relaxation. 1 In clinical practice it can be challenging to achieve complete immobility when the use of muscle relaxants are unnecessary, restricted, or contraindicated, such as may occur during neurosurgical procedures requiring assessment of motor-evoked potentials and/or electromyography. It may also be difficult to achieve reliable immobility in patients on anticonvulsant drugs, which shorten the half-life of muscle relaxants.
Muscle relaxants are not required in every surgical procedure and their avoidance may prevent adverse effects such as inadequate recovery of normal neuromuscular function and consequent postoperative respiratory failure. 2 Patients at high risk for these complications include those with certain neuromuscular diseases and preexisting respiratory impairment. 2 Finally, avoidance of neuromuscular block may aid in the prevention of awareness under anesthesia as movement will alert the practitioner to light anesthetic conditions. 2, 3 For these reasons, an anesthetic adjunct that reduces or abolishes patient movement in the absence of neuromuscular blockade would represent a substantive advantage to clinicians.
The purpose of pain is to signal acute injury and prevent further tissue damage by withdrawal from noxious stimuli. 4 Remifentanil, through its m-receptor agonist effect and ability to potentiate volatile anesthetics like isoflurane, has been shown to prevent withdrawal movement during surgical stimulation. 5 Studies have shown remifentanil's synergistic effects, with induction drugs such as propofol and volatile anesthetics. produce immobility have not been established with certainty.
The main objective of this study was to determine the dose-response relationship of remifentanil, when used in combination with 0.6% isoflurane, in reducing patient movement during surgical head pinning and incision for craniotomy. Head pinning and incision are used as surrogates for intraoperative stimuli, to achieve a standard, highly potent degree of stimulation in each patient, and to achieve our results early in the procedure and therefore decrease unnecessary movement risks during surgical brain manipulation. A secondary objective was to determine the frequency with which different remifentanil infusion doses produce hypotension and/or bradycardia.
MATERIALS AND METHODS
This study was approved by the Institutional Review Board of the Cleveland Clinic and written informed consent was obtained from each patient. Our study setting was in the neurosurgical operating room during elective craniotomy; patients were enrolled over a 2-year period. This was a prospective, randomized, clinical trial of 12 remifentanil infusion doses ranging from 0.10 to 0.21 m/kg/min to assess optimal dosing to prevent movement response to surgical stimulation. Computer-generated random numbers were used for group assignment.
The study excluded patients who were pregnant or nursing, had a Glasgow coma score <15, had contraindications to succinylcholine, underwent cerebral aneurysm clipping, were morbidly obese (body mass index >40), and had an American Society of Anesthesiologists physical status (ASA score) >3. Movement was continuously assessed according to predetermined criteria by the research investigator, as well as the neurosurgical, nursing, and anesthesiology teams, until 5 minutes after scalp incision at which time the study ended.
No premedication was given before induction of anesthesia. The administration of fluids was left to the discretion of the attending anesthesiologist, our standard practice calling for approximately 10 to 15 mL/kg crystalloid during induction and positioning.
Remifentanil infusion was started 2 to 4 minutes before induction, which was accomplished with lidocaine (10 to 20 mg to prevent pain after propofol administration), propofol (2 to 4 mg/kg), and succinylcholine (1 to 2 mg/kg) to facilitate tracheal intubation. Nondepolarizing muscle relaxants were avoided and the endtidal isoflurane concentration was kept at 0.6% in air/ oxygen throughout the study period.
After induction and tracheal intubation, an arterial line was placed and a second peripheral IV was started. Train-of-4 stimulation of the ulnar nerve was performed before head pinning to assure recovery from succinylcholine's neuromuscular blocking effect. As remifentanil plasma concentrations are reported to reach a steady state within 10 minutes of beginning an infusion, 8 we allowed head pinning to occur 15 minutes after the remifentanil infusion was started. No local anesthetic was administered to the patient's scalp before head pinning, which is standard practice at our institution. Demographic data including age, height, weight, and sex were obtained, as were heart rate, mean arterial pressure, systolic and diastolic blood pressure, and endtidal isoflurane concentration. Blood pressure was measured via an automated blood pressure cuff. These measurements were recorded immediately before remifentanil infusion, 5 minutes after remifentanil infusion was started, immediately after head pinning, 5 minutes after pinning, at skin incision, and 5 minutes after incision.
Patient movement was defined as either gross purposeful movement, such as reaching for the endotracheal tube or the head pins, coughing or bucking, chewing, swallowing, or grimacing, or minor limb movements, including movement distal to the elbow or the knees. Patient reactions were observed continuously by the anesthesiologist, operating room nurse, and research coordinator. Although efforts were made to keep observers blinded to the dose of remifentanil, it became apparent during the first portion of the study that blinding was incomplete. Thereafter, blinding procedures were tightened further.
Any patient movement resulted in termination of the study and immediate intervention to increase the depth of anesthesia. Hypotension was considered to occur if mean arterial pressure decreased to <60 mm Hg. 9 Bradycardia was defined as <60 beats/min. 10 The treatment of bradycardia and hypotension, once diagnosed, was left to the discretion of the clinician, and the use of vasopressor, and their doses were recorded.
Statistical Methods
The relationships between remifentanil dose, movement, hypotension, or bradycardia were analyzed using logistic regression models and summarized by odds ratios and 95% confidence intervals (CIs). Probit analysis was used to estimate the dose and 95% fiducial limits (analogous to CIs) corresponding to a given probability of having the outcome. The significance level was 0.05 for all hypotheses. Standard statistical software (SAS, Cary, NC) was used.
Sample size calculations indicated that 132 patients would be required with 11 patients for each of the 12 dosing steps. This number was chosen to be able to estimate the probability of movement with sufficient precision. Specifically, we planned to have a sufficiently narrow CI (width = 0.16, corresponding to a standard error of 0.041) from a logistic regression analysis for the probability of movement at a dose of 0.15 mg/kg/min assuming a true probability of movement of 0.20 at that dose.
RESULTS
Of 132 randomized patients, only 131 were available for analysis because of an infusion pump malfunction in 1 patient. Table 1 gives a summary of baseline factors such as age, body mass index, sex, and ASA score by dose. All randomized patients had elective surgery for either brain tumor resection or brain biopsy.
A total of 53 patients moved. All except 2 moved during head pinning. One moved before head pinning with ventilator setting changes; the other moved during head positioning. The type of movement observed was chewing and swallowing in 3 patients (5.6%), minor limb movement in 5 patients (9.4%), major purposeful limb movement in 6 patients (11.3%), coughing and bucking plus limb movement in 11 patients (20.7%), and coughing and bucking alone in 28 patients (52.8%).
Movement in response to surgical stimuli was observed in 65% (95% CI: 49%-79%) of patients at a remifentanil infusion rate of 0.10 mg/kg/min, and progressively decreased to 21% (95% CI: 11%-35%) as the infusion rate increased to 0.21 mg/kg/min (Table 2) .
Besides remifentanil dose, patient age was the only factor significantly associated with movement in response to surgical stimuli (P = 0.02). Higher age was associated with less movement, regardless of dosage. Specifically, a difference of 10 years of age was associated with a 36% (5% to 44%) less chance of movement (odds ratio 0.74, 95% CI: 0.56-0.95) ( Table 3) . To assess the impact of improved blinding procedures from early and late in the study, we included a phase variable (patients 1 to 93 vs. 94 onwards) in assessing confounders of the dose-movement relationship. No significant association was found between movement and phase (early vs. late) of the study, and no interaction between phase or any other variable and dose was found (Table 3) .
Hypotension occurred in 50% of patients receiving remifentanil at a rate of 0.13 mg/kg/min and in 75% of the patients receiving 0.20 mg/kg/min. CIs for estimated dose at a given probability of hypotension were not available due mainly to an outlier response at dosage 0.20 mg/kg/ min, where only 1/11 patients was hypotensive (Table 4 , Fig. 1) .
A similar trend was observed for bradycardia, which was experienced by 22 (95% CI: 12%-38%) patients at an infusion rate of 0.10 mg/kg/min remifentanil, and increased to 68 (95% CI: 52%-81%) patients at 0.21 mg/kg/min remifentanil. Similarly, the probability of bradycardia was 25% at a remifentanil infusion rate of 0.12 (0.08 to 0.13) mg/kg/min and increased to 50% at 0.17 (0.15 to 0.21) mg/kg/min remifentanil (Table 5 , Fig. 2 ). Thus, both hypotension and bradycardia increased at higher remifentanil infusion rates.
The observed data for movement in the study at doses of 0.10, 0.15, and 0.21 mg/kg/min, respectively, resulted in CI widths of 0.30, 0.18, and 0.24. Logistic regression CIs are naturally narrowest at the middle of the predictor (ie, the dose). Our observed CI width at 0.15 mg/kg/min is slightly wider than planned because the observed movement at that dose was larger than planned (44% vs. 20%), resulting in larger variance in the estimated probability of movement.
DISCUSSION
The results of our study demonstrate that higher doses of remifentanil lessen the risk of movement in the absence of muscle relaxants with surgical stimulation for elective craniotomy. The probability of preventing movement increased with remifentanil dose. On the basis of our observations, the remifentanil dose estimates for 50% and 75% reduction of the probability of movement were 0.13 and 0.19 mg/kg/min, respectively with 0.5 MAC isoflurane.
It is important to note that the probability of bradycardia was 33% at a remifentanil dose of 0.13 mg/ kg/min and almost doubled at 0.19 mg/kg/min. Similarly, patients dosed at 0.13 mg/kg/min had a 25% probability of hypotension, which increased to 50% at 0.19 mg/kg/ min. The hemodynamic instability induced by remifentanil is especially concerning because it was common at the doses required to reliably produce immobility. Our hemodynamic findings are consistent with the findings NA, no fiducial limits available for hypotension due to outlier dose 0.20 mg/kg/ min (Fig. 2) . of Bilgin et al 11 who while using a low-dose remifentanil (0.05 mcg/kg/min) combined with midazolam for conscious sedation during stereotactic brain biopsy found a low incidence of hypotension, similar to our findings while using low-dose remifentanil and Morgan et al 5 after the administration of a remifentanil bolus of 1.25 mcg/kg in combination with an induction dose of propofol for intubation found a higher incidence of bradycardia and hypotension when compared with the administration of propofol and suxamethonium, also similar to our findings at greater doses of remifentanil. 5, 11 Clinicians intending to employ remifentanil at a dose of 0.2 mcg/kg/min or higher to take advantage of the 80% probability of immobility should expect to have to support blood pressure pharmacologically.
Our results are also consistent with the findings of Lang et al, 6 who described the reduction of isoflurane MAC by remifentanil. These authors randomly assigned different remifentanil plasma concentrations (achieved via a computer-assisted continuous infusion device) to isoflurane-anesthetized patients. Movement was strictly defined as only gross purposeful muscular movement of the head and extremities following the criteria used for MAC determination by Quasha et al. 12 Lang et al showed that a remifentanil target plasma concentration of 1.37 ng/mL resulted in a 50% reduction in isoflurane MAC. 6 In our study, the administration of remifentanil at 0.13 mg/kg/min produced immobility in 50% of the patients when combined with 0.6% isoflurane. However, it is worth noting that the definition of movement in our study included both gross purposeful muscular movement, as well as minor limb movement, coughing, swallowing, chewing, and grimacing. Because any movement during head-pin placement is undesirable and is likely a sign of inadequate anesthesia, we believe our definition of movement and study results to have superior relevance to clinical practice.
Our study had several limitations which should be considered when interpreting our results. First, although the response to surgical stimulation was assessed using criteria established at the beginning of the study, it was not always possible to keep the observer blinded to the dosing group assignment. This could have introduced bias in the interpretation of the patient's movement response. In our multivariable statistical model, we assessed whether the relationship between movement and dose was different for the first 93 patients compared with the last 39 (ie, those with tighter blinding) and it was not. Although this does not prove absence of bias from unblinding, it is unlikely that our results were affected in a major way. We believe this to be the case in part because our definition of movement required no clinical judgment over what constituted movement, as all movement was scored as a positive response. Furthermore, previous investigators did not consider blinding procedures necessary to make valid conclusions about dose-response relationships. 6, 12 Second, the dose range studied extended only from 0.10 to 0.21 mcg/kg/min. It was not possible to find a dose within this range at which all patients were immobile. It is therefore unknown whether this dose indeed exists. Third, we did not measure plasma remifentanil concentrations so we cannot say for certain that the infusion doses employed truly resulted in a progressively higher plasma effect. Nevertheless, the remifentanil dose is clinically thought of as an infusion dose and therefore our findings should be relevant to clinical practice.
Our results suggest that higher doses of remifentanil substantially lessen the risk of movement with potent surgical stimulation in the absence of neuromuscular blockade. Clinicians should bear in mind that, even at our maximum dose of remifentanil (0.21 mcg/kg/min) a 20% chance of movement was observed. Adjunctive therapy is needed to ablate movement reliably, and to counteract the hypotensive effect of remifentanil. Further studies are required to determine the optimal combination of remifentanil and isoflurane to ablate any movement.
